Figure 3.

Expression of SKA2 in lung cancer. (a) Immunofluoresence analysis of SKA2 in A549 cells under basal and treatment conditions as indicated. (b) Immunoperoxidase staining of SKA2 in human SCLC xenografts in athymic mice and primary human lung adenocarcinoma. Antibody controls (antibody blocked with peptide and no primary) are presented, as indicated. Graph shows small-scale pilot analysis of SKA2 expression in six primary human lung cancers. At least eight sections from each tumour were scored by a masked observer against a colour card (0–3 for intensity).